Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 15, 2019Clinical Cancer ResearchOpen Access

Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

SHSara A. HurvitzCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South AfricaMMMiguel MartínHospital General Universitario Gregorio MarañónMPMichael F. PressUniversity of Southern California

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hurvitz et al. (2019) studied this question.

synapsesocial.com/papers/69df2b1cd9e0feb21c591eaahttps://doi.org/10.1158/1078-0432.ccr-19-1425
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine2014 · 577 citations
  2. 2MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer2019 · 696 citations
  3. 3A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer2016 · 172 citations
  4. 4Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer2016 · 805 citations
  5. 5The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade2018 · 477 citations